Utkan Demirci, PhD, is a professor with tenure at Stanford University School of Medicine at the Canary Center at Stanford for Cancer Early Detection. Before moving to Stanford, he was an associate professor of Medicine and Health Sciences and Technology at Brigham and Women’s Hospital, Harvard Medical School (HMS) and Harvard- Massachusetts Institute of Technology (MIT) Health Sciences and Technology. His group is focused on the development of point-of-care technologies and creating microfluidic platforms for sorting rare cells and exosomes for infectious diseases and cancer. His early work founded the basics of 3-D bioprinting of cells and biomaterials.
As an academic entrepreneur, Dr. Demirci’s seminal work in microfluidics has led to the development of innovative platform technologies in medicine with broad applications in label-free rare cell sorting and point-of-care diagnostics. His lab has developed various microfluidic, bioprinting platforms with broad medical applications, including a portable biosensor for monitoring HIV infected CD4+ T cells rapidly at point-of-care, which was successfully tested on patients in Tanzania. Some of his earlier developments in innovative microfluidic technologies have been widely used by fertility clinics around the world in assisted reproductive technologies that have led to over 10,000 live births globally. These FDA approved and CE marked products continue to serve patients across the globe.
Dr. Demirci is the recipient of many prestigious awards, including the Academy for Radiology & Biomedical Imaging Research (ARBIR) Distinguished Investigator Award, MIT TR-35 Award, Harvard Medical School-Young Investigator Award, Stanford Basic Scientist of the Year Award, Brigham and Women’s Hospital-Bright Future Award, IEEE EMBS Early Career Award, IEEE EMBS Translational Science Award, NSF CAREER Award, Coulter Foundation Early Career Award and Chinese International Young Scientist Award. He is also a fellow-elect of the American Institute of Medical and Biological Engineering. Dr. Demirci holds 25 issued or pending patents, provisional applications and invention disclosures that have been licensed to numerous companies, and he is the founder of such startups as DxNow, LevitasBio, Koek Biotechnology. He has published 148 articles, 24 book chapters and editorials, and has edited four books, and serves as an editorial board member for various peer-reviewed journals.
Özet başvuruları son tarihi 1 Ekim 2019 dur. Başvurularda görülen yoğunluk ve sözlü sunum sayısının fazlalığı nedeni ile en kısa sürede özetlerinizi yükleyiniz.
Erken kayıt son tarihi 1 EYLÜL 2019 dur. Katılımcıların kayıt ücretlerini bir an önce yatırmalarını hatırlatırız.
Özet kabul süreci başlamıştır. Özetlerinizi "Kongre Hakkında" butonundaki "Özet Gönderim" bölümünden yapabilirsiniz.
Kayıt ücretini yatıran katılımcıların, dekontunun bir nüshasını
adresine göndermeleri gerekmektedir.
Erken Kayıt İçin Son Tarih 01/Eylül/2019. Katılım bedelleri "Kongre Hakkında" sekmesinde bulunan "Katılım Ücretleri" sekmesinde ilan edilmiştir.
2. EBAT Kongresi katılımcılarının kongre sitesindeki "Online Kayıt" sekmesinden kayıt olmaları gerekmektedir.